LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Accueil・Liste d'Actions・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Fermé

SecteurSoins de santé

3.93 5.65

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.7199999999999998

Max

3.95

Chiffres clés
By Trading Economics
Revenu	-15M -40M
Ventes	8.2M 50M
Marge bénéficiaire	-80.43
Employés	435
EBITDA	-19M -42M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+5.54% upside

Dividendes
By Dow Jones
Prochains Résultats	7 mai 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	277M 1.4B
Ouverture précédente	-1.72
Clôture précédente	3.93

Sentiment de l'Actualité

By Acuity

50%

180 / 347 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

2.02 / 2.115 Support & Résistance

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

6 mai 2026, 23:41 UTC

Résultats

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 mai 2026, 21:40 UTC

Résultats

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 mai 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 mai 2026, 23:13 UTC

Résultats

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 mai 2026, 23:13 UTC

Résultats

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 mai 2026, 23:12 UTC

Résultats

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 mai 2026, 23:11 UTC

Résultats

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 mai 2026, 23:11 UTC

Résultats

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 mai 2026, 23:11 UTC

Résultats

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 mai 2026, 23:11 UTC

Résultats

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 mai 2026, 23:11 UTC

Résultats

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 mai 2026, 23:11 UTC

Résultats

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 mai 2026, 23:07 UTC

Résultats

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 mai 2026, 23:06 UTC

Résultats

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 mai 2026, 23:06 UTC

Résultats

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 mai 2026, 23:05 UTC

Résultats

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 mai 2026, 23:04 UTC

Résultats

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 mai 2026, 22:50 UTC

Résultats

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 mai 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 mai 2026, 22:11 UTC

Résultats

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 mai 2026, 22:11 UTC

Résultats

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 mai 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 mai 2026, 21:58 UTC

Résultats

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mai 2026, 21:47 UTC

Market Talk

Résultats

Costco Posts 13% Sales Growth in April -- Market Talk

6 mai 2026, 21:46 UTC

Résultats

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 mai 2026, 21:40 UTC

Résultats

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mai 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 mai 2026, 21:32 UTC

Actions en Tendance

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 mai 2026, 21:29 UTC

Résultats

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

5.54% hausse

Prévisions sur 12 Mois

Moyen 4 USD 5.54%

Haut 5 USD

Bas 3 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

6 ratings

Achat

Maintien

Vente

Basé sur 6 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There are no events.

Sentiment

By Acuity

180 / 347Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.